Well, I’m enjoying that pleasant feeling you get when you haven’t been punked.
Champagne corks popping in Maryland, I expect, as the Whelans and crew are celebrating some long overdue FDA news tonight. Special shout out to Mr. Andrew Whelan, who always took my (rare) phone calls.
The FDA has granted OTC clearance (see below). More will be revealed, but believe me this is huuuge.
You gotta love this stock if you’re a zombie fan, because this thing keeps rising from the dead.
What happens Monday or how to play it–your guess is as good as mine. With this type of announcement, you are better off being already in, much better.
Congratulations to all the stalwarts of this stock. I admit I was about to wring some necks…soon, that’s when. What a difference a day makes.
Good luck to all the longs. Monday it’s the Hunger Games arena.We waited a long time for some fireworks, and it looks like we’ll get them. I feel vindicated, as do we all. One hates to put trust in ones scientific judgment and have a washout, but it looks like the takeaway is the FDA crunched the data and said it was efficacious.
Here is a significant point–BIEL has several other products waiting in the wings. If the FDA approved these two, the others stand a much better chance.
BioElectronics ulationsCorporation Announces US FDA OTC Clearances For Drug-free ActiPatch® Musculoskeletal Pain Therapy
FREDERICK, MD, USA, February 3, 2017 — BioElectronics Corporation (OTC Pink: BIEL), the maker of wearable pain therapy devices, announced today that it has received over-the-counter use clearance from the US FDA for ActiPatch for the adjunctive treatment of musculoskeletal pain related to (1) plantar fasciitis of the heel; and (2) osteoarthritis of the knee.
BioElectronics is an electroceutical company that develops wearable, neuromodulation devices to safely mitigate neurological diseases and improve quality of life. Our innovative pulsed shortwave therapy technology (PSWT) that uses low power pulsed electromagnetic fields regulate electrical activity of the nervous system. The neuromodulation basis of PSWT presents significant opportunities for BioElectronics to develop optimized technology for diabetic neuropathy, postoperative surgery, chronic wounds, and other applications.
Our current OTC product line includes ActiPatch® Musculoskeletal Pain Therapy, Allay® Menstrual Pain Therapy, Smart Insole™ Heel Pain Therapy, and RecoveryRx® Post-operative and Chronic Wounds Therapy. The flagship product of BioElectronics Corporation is the ActiPatch® Musculoskeletal Pain Therapy, developed to relieve chronic pain. ActiPatch is a drug-free, wearable nonprescription medical device that provides 720-hours (90, 8-hour treatments) of on/off therapy for $30.00 retail. Most users obtain relief with only 8 hours per day of use, so the device will generally last several months, depending on use. ActiPatch Provides:
- Impressive Efficacy
- No harmful side effects
- A 50% Reduction in Medication Use, including opioids
- Exceptional Consumer Acceptance
- Demonstrated Marketability
- An adjunctive or alternative therapy to pain killers, including narcotics.
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: For more information, please visit www.bielcorp.com.